All In Biotech

Drug Trial Radar · NCT04986423

ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer

A Randomized Phase 2b Study of ZEN003694 in Combination With Enzalutamide Versus Enzalutamide Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Last checked: Nov 19, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Sep 8, 2021

Primary completion

Dec 2026

Study completion Jun 2027

Sponsor

Lead sponsor
Zenith EpigeneticsIndustry
Sponsor type
Industry
Collaborators
Astellas Pharma Inc; Newsoara Biopharma Co., Ltd.
First posted
Aug 2, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, randomized, Phase 2b study of ZEN003694 in combination with enzalutamide vs. enzalutamide monotherapy in patients with mCRPC who have progressed on prior abiraterone by PCWG3 criteria. Disease must have progressed on only abiraterone by PCWG3 criteria prior to study entry. The patient population will be separated into two cohorts: Cohort A: Patients with poor response to prior abiraterone defined as: * Abiraterone started in hormone-sensitive prostate cancer (HSPC) disease setting: \< 12 months duration on abiraterone or failure to achieve PSA nadir of 0.2 ng/mL while taking abiraterone, or; * Abiraterone started in castrate-resistant prostate cancer (CRPC) disease setting: \< 6 months duration on abiraterone or failure to achieve PSA50 response while on abiraterone Cohort B: Patients with response to prior abiraterone, defined as: * Abiraterone started in hormone-sensitive prostate cancer (HSPC) disease setting: ≥ 12 months duration on abiraterone and nadir PSA \< 0.2 ng/mL, or; * Abiraterone started in castrate-resistant prostate cancer (CRPC) disease setting: ≥ 6 months duration on abiraterone and confirmed PSA50 response

Conditions

  • Metastatic Castration-Resistant Prostate Cancer

Interventions

  • ZEN003694Drug

    72 mg PO QD

  • EnzalutamideDrug

    160 mg PO QD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort A: Radiographic progression-free survival (rPFS) by BICRTime frame: Randomization up to 30 months

Locations

31 sites in 2 countries. Site status is shown where the registry gives one.

  • California Research Institute

    Los Angeles, California · Recruiting

  • University of California, San Francisco

    San Francisco, California · Recruiting

  • Innovative Clinical Research Institute

    Whittier, California · Recruiting

  • Colorado Urology

    Lakewood, Colorado · Recruiting

  • D&H Cancer Research Center, LLC

    Margate, Florida · Recruiting

  • BRCR Global

    Plantation, Florida · Recruiting

  • Hematology Oncology Clinic

    Baton Rouge, Louisiana · Withdrawn

  • Maryland Oncology Hematology, P.A.

    Columbia, Maryland · Recruiting

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan · Recruiting

  • Weill Cornell Medical College - New York Presbyterian Hospital

    New York, New York · Completed

  • Messino Cancer Center

    Asheville, North Carolina · Recruiting

  • Northwest Cancer Specialists, P.C.

    Portland, Oregon · Recruiting

  • Urology Associates, P.C.

    Nashville, Tennessee · Recruiting

  • Texas Oncology - Central South

    Austin, Texas · Recruiting

  • Virginia Cancer Specialists

    Fairfax, Virginia · Recruiting

  • Seattle Cancer Care Alliance

    Seattle, Washington · Recruiting

  • Anhui Provincial Hospital

    Hefei, Anhui, China · Recruiting

  • Chongqing Cancer Hospital

    Chongqing, Chongqing Municipality, China · Recruiting

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • Tongji Hospital of Tongji Medical College, Huazhong University of Science & Technology

    Wuhan, Hubei, China · Recruiting

  • Hubei Cancer Hospital

    Wuhan, Hubei, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Recruiting

  • Nanjing Drum Tower Hospital

    Nanjing, Jiangsu, China · Recruiting

  • Liaoning Cancer Hospital

    Shenyang, Liaoning, China · Withdrawn

  • The First Affiliated Hospital of Xi'an Jiaotang University

    Xi'an, Shaanxi, China · Recruiting

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanghai Tenth People's Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • First Hospital of Shanxi Medical University

    Taiyuan, Shanxi, China · Recruiting

  • Sichuan Provincial People's Hospital

    Chengdu, Sichuan, China · Recruiting

  • Zhejiang Provincial People's Hospital

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.